Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 28, 2022.

Foralumab, an anti-CD3 monoclonal antibody, has been previously assessed in diseases such as progressive multiple sclerosis and Crohn disease, as well as in patients with mild to moderate COVID-19.

Here's some of what is coming soon to NeurologyLive® this week.

Changes in plasma pTau217 and GFAP levels from donanemab significantly correlated with percent change in amyloid plaque level as measured by amyloid PET imaging.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the European Committee for Treatment and Research in Multiple Sclerosis.

The composite score, which consisted of 6 linguistic features and 3 acoustic features, was shown to be sensitive to measures of disease progression, with a potential to help understand treatment response.

Neurology News Network for the week ending October 22, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 21, 2022.

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience during the Medical Crossfire session on the Alheimer pipeline that he took part in at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 7 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Stephen Krieger, MD; Richard Isaacson, MD; and Jessica Ailani, MD. [LISTEN TIME: 24 minutes]

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine provides commentary about his time at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 4 minutes]

The director of NYU Langone’s Alzheimer’s Disease Research Center discussed noticeable advancements within the field of Alzheimer disease in recent years and how they contribute to gaining a better understanding of the disease. [WATCH TIME: 5 minutes]

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 3 minutes]

In a phase 2 study, fosgonimeton showed positive effects on measures of cognition, function, and neurodegeneration when taken as a monotherapy, prompting an unblinded interim analysis.

Here's some of what is coming soon to NeurologyLive® this week.

The launch of the medication was done in phases, as wholesalers received first-line formulary coverage in September 2022, while a nationwide launch is expected in 2023.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 14, 2022.

The odds of having memory worsening at follow-up after 3 years were almost 30% greater for those who exhibited deteriorating insomnia status than those who showed signs of improvement.

The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology discussed current knowns and unknowns about the pathology of Alzheimer disease. [WATCH TIME: 4 minutes]

In a cohort of nearly 600,000 individuals, the combination of dementia diagnosis and presence of psychiatric comorbidity significantly increased the risk of suicide.

The TRACK-TBI cohort study revealed that patients with traumatic brain injury and a GCS score of 3 to 12 had a significant increase in the accuracy of prognostic accuracy of IMPACT models.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is insomnia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 7, 2022.

When hydromethylthionine mesylate was compared with publicly available placebo decline data, the treatment effects of cognitive and functional decline are about 3-fold larger over 18 months.

Expert clinicians offer their perspectives on developmental milestones for children, the NMSOD patient perspective, effective treatments for insomnia, ALS, diabetic and inflammatory neuropathies, and lecanemab in early Alzheimer disease.

In 2 phase 3 randomized placebo-controlled trials, findings showed that although crenezumab was well tolerated, it did not reduce clinical decline in participants with early Alzheimer disease.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

With diagnosis rates of Alzheimer disease increasing, Tabby Khan, MD, MPH, spoke to the need to focus on cognitive decline in younger patient populations.